Clopidogrel

More adults with type 2 diabetes achieved guideline-recommended strategies for stroke prevention in 2018 compared with 2001, but further improvements are needed, according to study findings published in Diabetes Care.

ATLANTA — In this Healio exclusive, the past Chair of SCAI SHOCK provided a video commentary on two trials presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.

ATLANTA — Clopidogrel monotherapy after 12 months of event free post-PCI dual antiplatelet therapy was associated with fewer MACCE and bleeding events vs. aspirin monotherapy in high bleeding risk patients, a speaker reported.

Eating at least two servings of avocado per week may lower the risk for CVD and coronary heart disease when compared with no avocado consumption, according to a recent study.

In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported.

P2Y12 inhibitor plus anti-coagulation vs. anticoagulation alone in noncritically ill patients with COVID-19.

Treatment with the IV P2Y12 inhibitor cangrelor reduced the number of early ischemic events after PCI, primarily MI and stent thrombosis, compared with oral clopidogrel, according to the results of the CHAMPION PHOENIX trial.

Dual antiplatelet therapy that combined aspirin with either ticagrelor or clopidogrel outperformed aspirin alone in minor ischemic stroke and transient ischemic attack, according to results of a network meta-analysis.

In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation did not extend survival or lessen disease severity, according to results of the ACTIV-4a trial.

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).